TBCRC 033: A randomized phase II study of adjuvant trastuzumab emtansine (T-DM1) vs paclitaxel (T) in combination with trastuzumab (H) for stage I HER2-positive breast cancer (BC) (ATEMPT)Sara M. Tolaney,Lorenzo Trippa,William Barry,Jiani Hu,Chau Dang,Denise Yardley,Steven Isakoff,Vicente Valero,Meredith Faggen,Therese Mulvey,Ron Bose,Douglas Weckstein,Antonio Wolff,Katherine Reeder-Hayes,Hope Rugo,Bhuvaneswari Ramaswamy,Dan Zuckerman,Lowell Hart,Vijayakrishna K. Gadi,Michael Constantine,Kit Cheng,Frederick Briccetti,Bryan Schneider,Merrill Garrett,Kelly Marcom,Kathy Albain,Patricia DeFusco,Nadine Tung,Blair Ardman,Rita Nanda,Rachel Jankowitz,Michelle Demeo,Ann Partridge,Harold Burstein,Eric P. Winer,Ian KropCANCER RESEARCH(2020)引用 29|浏览65暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要